Organogenesis Ebitda from 2010 to 2024

ORGO Stock  USD 4.05  0.03  0.75%   
Organogenesis Holdings EBITDA yearly trend continues to be very stable with very little volatility. EBITDA is likely to drop to about 18.5 M. During the period from 2010 to 2024, Organogenesis Holdings EBITDA quarterly data regression pattern had sample variance of 912.1 T and median of (208,698). View All Fundamentals
 
EBITDA  
First Reported
2016-03-31
Previous Quarter
-9.7 M
Current Value
12.7 M
Quarterly Volatility
10.3 M
 
Yuan Drop
 
Covid
Check Organogenesis Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Organogenesis Holdings' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 2.1 M or Selling General Administrative of 149.1 M, as well as many indicators such as Price To Sales Ratio of 2.26, Dividend Yield of 0.0 or PTB Ratio of 1.83. Organogenesis financial statements analysis is a perfect complement when working with Organogenesis Holdings Valuation or Volatility modules.
  
Check out the analysis of Organogenesis Holdings Correlation against competitors.
To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.

Latest Organogenesis Holdings' Ebitda Growth Pattern

Below is the plot of the Ebitda of Organogenesis Holdings over the last few years. It is Organogenesis Holdings' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Organogenesis Holdings' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Organogenesis Ebitda Regression Statistics

Arithmetic Mean10,146,700
Geometric Mean2,819,312
Coefficient Of Variation297.65
Mean Deviation22,452,363
Median(208,698)
Standard Deviation30,201,266
Sample Variance912.1T
Range127.9M
R-Value0.49
Mean Square Error743.5T
R-Squared0.24
Significance0.06
Slope3,329,522
Total Sum of Squares12769.6T

Organogenesis Ebitda History

202418.5 M
202336 M
202240.3 M
202187 M
202037.2 M
2019-20 M
2018-40.9 M

About Organogenesis Holdings Financial Statements

Organogenesis Holdings investors utilize fundamental indicators, such as Ebitda, to predict how Organogenesis Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
EBITDA36 M18.5 M

Pair Trading with Organogenesis Holdings

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organogenesis Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organogenesis Holdings will appreciate offsetting losses from the drop in the long position's value.

Moving against Organogenesis Stock

  0.86TCHH Trustcash HoldingsPairCorr
  0.79JNJ Johnson Johnson Sell-off TrendPairCorr
  0.78PFE Pfizer Inc Fiscal Year End 4th of February 2025 PairCorr
  0.74MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.73ME 23Andme HoldingPairCorr
The ability to find closely correlated positions to Organogenesis Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organogenesis Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organogenesis Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organogenesis Holdings to buy it.
The correlation of Organogenesis Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organogenesis Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organogenesis Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Organogenesis Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Organogenesis Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Organogenesis Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organogenesis Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organogenesis Holdings Stock:
Check out the analysis of Organogenesis Holdings Correlation against competitors.
To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
3.5
Earnings Share
(0.05)
Revenue Per Share
3.446
Quarterly Revenue Growth
0.061
Return On Assets
0.0164
The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.